Member Info for Ozaztec

Trinity Delta view: Avacta is a pure play oncology company centred on the proprietary pre|CISION platform and PDC (peptide drug conjugate) assets, with management striving to reduce shareholder dilution as these advance towards near- and mid-term value inflection points. Faridoxorubicin, currently the lead programme, demonstrates the ability of pre|CISION to deliver a potent, toxic payload to the tumour microenvironment (TME) with minimal systemic effects; AVA6103, the lead Gen Two programme exploiting a sustained release mechanism for its exatecan payload, is in Phase I studies; with the lead Gen Three programme expected to complete IND-enabling studies. In our view, the key takeaway from this raise is that institutional investors (and management) are prepared to participate in a placing at market prices, suggesting solid confidence in the platform’s future potential and management’s ability to deliver it. Following the raise, we suspend valuation and forecasts. For context our last published valuation was £471m ($603m) or 103p/share.

What has always amazed me is how Avacta has always been able to keep “A Lid” on the progress of trials. No leaks, complete control. Very tightly and well run company. There must be hundreds involved that have seen and know that it works, not a squeak until Avacta wants the world to know!

Carla has gone to Merck!

Avacta is pleased to announce that Consilium Strategic Communications has been appointed as the Company's investor and media relations advisors with immediate effect. consilium-comms.com #AVCT

Yes, a number of cancer experts have endorsed Avacta Plc's Affimer and prelCISION platforms. These experts include:

Professor Alan Melcher, a leading cancer researcher at the University of Leeds
Professor David Cunningham, a leading cancer surgeon at the University of Glasgow
Professor David Thomas, a leading cancer oncologist at the University of Manchester
These experts have endorsed Avacta's platforms because they believe that the platforms have the potential to revolutionize the way that cancer is treated. Affimers are smaller and more stable than antibodies, which makes them easier to manufacture and more cost-effective. prelCISION uses a combination of Affimers and nanoparticles to deliver a diagnostic agent to a tumor. These features make Avacta's platforms potentially more effective and less expensive than traditional cancer therapies.

It is important to note that Avacta is still a clinical-stage company. Its drugs have not yet been approved by the FDA, and there is no guarantee that they will be successful. However, the endorsements from these experts are a positive sign that Avacta's platforms have the potential to make a significant impact on the treatment of cancer.

Here are some quotes from these experts:

"Avacta's Affimer technology has the potential to revolutionize the way that cancer is treated. Affimers are smaller and more stable than antibodies, which makes them easier to manufacture and more cost-effective. This could lead to the development of new and more effective cancer therapies." - Professor Alan Melcher
"Avacta's prelCISION platform has the potential to improve the accuracy of cancer diagnostics. By combining Affimers and nanoparticles, Avacta can deliver a diagnostic agent to a tumor with greater precision. This could lead to the development of new and more effective cancer treatments." - Professor David Cunningham
"Avacta's platforms have the potential to make a significant impact on the treatment of cancer. I am excited to see how these platforms develop in the future." - Professor David Thomas

A number of organizations have endorsed Avacta Plc's Affimer and prelCISION platforms, including:

The Wellcome Trust, a global charitable foundation that supports biomedical research
The British Business Bank, a government-owned development bank that invests in small and medium-sized businesses
The Scottish Enterprise, a government agency that promotes economic development in Scotland
AstraZeneca, a global pharmaceutical company
Merck, a global pharmaceutical company
These organizations have endorsed Avacta's platforms because they believe that the platforms have the potential to revolutionize the way that cancer is treated. Affimers are smaller and more stable than antibodies, which makes them easier to manufacture and more cost-effective. prelCISION uses a combination of Affimers and nanoparticles to deliver a diagnostic agent to a tumor. These features make Avacta's platforms potentially more effective and less expensive than traditional cancer therapies.

It is important to note that Avacta is still a clinical-stage company. Its drugs have not yet been approved by the FDA, and there is no guarantee that they will be successful. However, the endorsements from these organizations are a positive sign that Avacta's platforms have the potential to make a significant impact on the treatment of cancer.

Avacta Plc has a number of patents that cover its Affimer and prelCISION platforms. These patents are currently in force and have not been challenged in court. Avacta has also licensed its Affimer technology to a number of pharmaceutical companies, including AstraZeneca and Merck. These companies are using Avacta's technology to develop new drugs for a variety of diseases.

The evidence suggests that Avacta Plc's patents work. The company has a number of clinical trials underway, and its technology has been licensed to a number of pharmaceutical companies. These are all positive signs that Avacta's patents are valuable and that the company is on the right track to developing new drugs.

However, it is important to note that Avacta is still a clinical-stage company. Its drugs have not yet been approved by the FDA, and there is no guarantee that they will be successful. Avacta's investors are taking a risk by investing in the company, and there is no guarantee that they will be rewarded for their investment.

For amusement only!

This is Googles’ “Bard” on our subject;-

Avacta Plc is a clinical-stage oncology drug company headquartered in Wetherby, West Yorkshire, United Kingdom. The company was founded in 2002 and is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms.

Affimer is a class of biotherapeutic based on a naturally occurring human protein. Affimers are smaller and more stable than antibodies, which makes them easier to manufacture and more cost-effective. Avacta is developing a number of Affimer-based cancer immunotherapies, including AVCT-0001, AVCT-0002, and AVCT-0003.

prelCISION is a platform for developing targeted cancer diagnostics. prelCISION uses a combination of Affimers and nanoparticles to deliver a diagnostic agent to a tumor. Avacta is developing a number of prelCISION-based cancer diagnostics, including AVCT-0004 and AVCT-0005.

Avacta has a number of clinical trials underway, including a Phase 1/2 trial of AVCT-0001 in patients with advanced solid tumors, a Phase 1 trial of AVCT-0002 in patients with advanced melanoma, and a Phase 1 trial of AVCT-0003 in patients with advanced colorectal cancer. Avacta is also developing a number of preclinical programs.

Avacta is a privately held company. The company's investors include the Wellcome Trust, the British Business Bank, and the Scottish Enterprise.

HL fees have been deducted this morning with cash available on your account reducing.
Best check that your cash balance covers your extra shares entitlement/request,

GLA

SolGold Equador

SolGold signed with @Presidencia_Ec @LassoGuillermo a preliminary commitment to enter into the Exploration Investment Contract for the Cascabel mining project. The detail of the investment will contemplate several aspects of work, among them, Environmental Management, Community and Social Contribution, as well as, generation and maintenance of employment positions, among others. This event represents a milestone for the sector due to SolGold's permanent commitment to responsible mining in the country, which is strengthened through the trust that the Government grants to foreign capital.

https://twitter.com/mylesmcnulty/status/1447981705004990473?s=21

Hope he is correct!!

Makes sense to me, hope he’s correct!

https://www.tga.gov.au/covid-19-test-kits-included-artg-legal-supply-australia We’re not on the list of approved suppliers for Australia, Why not? Or can someone find us hidden in the list.

Today we launch the Avacta Diagnostics Twitter channel. Here we will share news and updates on the diagnostics industry as well as the latest developments on our AffiDX® IVD tests, starting with the AffiDX® SARS-CoV-2 #COVID19 antigen lateral flow test.

CO, thank you, I was getting worried that no one knew! Still trying to digest your reply but thanks for your time and please check my profile, I’ve been in AVCT for over 18 months and have always been positive.

Can anyone assist????

Avacta Group PlcSum change: 0.00 million GBX
# From To StartPrice EndPrice Short-% #stocks Change
1. 2021-08-12 2021-08-20 (ongoing) - - 0.63% - -
2. 2021-07-07 2021-08-11 - - 0.52% - -

Can someone explain this to some of us not so wise!?

Avacta Group PlcSum change: 0.00 million GBX
# From To StartPrice EndPrice Short-% #stocks Change
1. 2021-08-12 2021-08-20 (ongoing) - - 0.63% - -
2. 2021-07-07 2021-08-11 - - 0.52% - -

Can someone explain this to some of us not so wise!?

The Annual General Meeting will be held on Monday, 28 June 2021 at 10.00 a.m. at the offices of Walker Morris LLP at 33 Wellington Street, Leeds LS1 4DL.

In the light of the Coronavirus pandemic, shareholders are strongly urged to appoint the chairman of the Meeting as his or her proxy as, given the Coronavirus situation and current Government advice on public gatherings, attendance in person is not advised.

To enable shareholders to raise any questions they may have prior to the AGM, the Company will be providing a Business Update webinar led by Alastair Smith, Chief Executive Officer which will take place at 10:00am on Monday 21 June 2021.

The webinar is open to all shareholders and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Shareholders can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar:

https://www.investormeetcompany.com/avacta-group-plc/register-investor

Shareholders who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited.